

**LISTING OF CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method of specifically activating cytotoxic T lymphocytes ~~in vivo~~ in an animal having ~~malignant cells~~ a neoplasm that expresses a Her-2/Neu protein, the method comprising the step of ~~immunizing~~ administering the polypeptide of SEQ ID NO:12 to said animal having said neoplasm that expresses said Her-2/Neu protein ~~with the polypeptide of SEQ ID NO:12.~~

Claims 2-60 (canceled)

Claim 61 (currently amended): A method of treating a patient having a ~~tumor~~ neoplasm and in need of treatment of said ~~tumor~~ neoplasm, wherein cells of said ~~tumor~~ neoplasm express a Her-2/Neu protein, the method comprising the step of administering a polypeptide having the amino acid sequence VMAGVGSPYV (SEQ ID NO:12) to the patient having said neoplasm wherein cells of said neoplasm express said Her-2/Neu protein.

Claim 62 (previously presented): The method of claim 61, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- Claim 63 (previously presented): The method of claim 61, wherein said polypeptide is linked to a carrier.
- Claim 64 (previously presented): The method of claim 61, wherein said polypeptide is administered to said patient as a homopolymer.
- Claim 65 (previously presented): The method of claim 61, further comprising the step of administering a second component to said patient, wherein said second component primes cytotoxic T lymphocytes (CTLs) for activation.
- Claim 66 (previously presented): The method of claim 65, wherein the second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 67 (previously presented): The method of claim 61, further comprising the step of administering a second polypeptide to said animal.
- Claim 68 (previously presented): The method of claim 67, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).
- Claim 69 (previously presented): The method of claim 1, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- Claim 70 (previously presented): The method of claim 1, wherein said polypeptide is linked to a carrier.
- Claim 71 (previously presented): The method of claim 1, wherein said polypeptide is administered to said animal as a homopolymer.
- Claim 72 (previously presented): The method of claim 1, wherein said immunizing step further comprises administering a second component to said animal, wherein said second component primes said CTLs for activation.
- Claim 73 (previously presented): The method of claim 72, wherein said second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 74 (previously presented): The method of claim 1, wherein the immunizing step further comprises administering a second polypeptide to said animal.
- Claim 75 (previously presented): The method of claim 74, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).
- Claim 76 (new): The method of claim 61, wherein said neoplasm overexpresses said Her-2/Neu protein.
- Claim 77 (new): The method of claim 1, wherein said neoplasm overexpresses said Her-2/Neu protein.

- Claim 78 (new): The method of claim 77, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
- Claim 79 (new): The method of claim 77, wherein said polypeptide is linked to a carrier.
- Claim 80 (new): The method of claim 77, wherein said polypeptide is administered to said animal as a homopolymer.
- Claim 81 (new): The method of claim 77, further comprising a step of administering a second component to said animal, wherein said second component primes said cytotoxic T lymphocytes (CTLs) for activation.
- Claim 82 (new): The method of claim 81, wherein said second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 83 (new): The method of claim 77, further comprising a step of administering a second polypeptide to said animal.
- Claim 84 (new): The method of claim 83, wherein said second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).